PPAR Agonists and Cardiovascular Disease in Diabetes
Author Information
Author(s): Anna C. Calkin, Merlin C. Thomas
Primary Institution: JDRF Center for Diabetes Complications, Baker Heart Research Institute, Melbourne, VIC, Australia
Hypothesis
Do PPAR agonists reduce cardiovascular risk in patients with diabetes?
Conclusion
PPAR agonists have independent anti-atherosclerotic actions, but their clinical benefits in reducing cardiovascular events in diabetes remain uncertain.
Supporting Evidence
- PPAR agonists can improve lipid profiles and insulin sensitivity in patients with diabetes.
- Clinical trials show mixed results regarding the cardiovascular benefits of PPAR agonists.
- Some PPAR agonists have been associated with increased cardiovascular events.
Takeaway
PPAR agonists are medications that help manage diabetes and may also protect the heart, but they can sometimes cause problems like fluid retention.
Methodology
The review examines the effects of PPAR agonists on cardiovascular disease in diabetes, discussing their mechanisms and clinical trial outcomes.
Limitations
The clinical efficacy of PPAR agonists is controversial, with mixed results in trials regarding their cardiovascular benefits.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website